Therapy of X-linked adrenoleukodystrophy
Open accessThe DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
X-linked adrenoleukodystrophy (X-ALD; OMIM #300100) is caused by defects of the ABCD1 gene on chromosome Xq28, resulting in an impairment of peroxisomal beta-oxidation and the accumulation of saturated very long chain fatty acids (VLCFAs). Primary manifestations occur in the CNS, the adrenal cortex and the testes' Leydig cells. The clinical presentation shows a marked variability which is not explained by the different X-ALD genotypes. Phenotypes range from rapidly progressive cerebral disease with childhood (childhood cerebral ALD [CCALD]) or adulthood (adult cerebral ALD [ACALD]) onset leading to death within a few years, over adult-onset adrenomyeloneuropathy (AMN) with or without focal CNS demyelination, AMN converting into a rapidly progressive, cerebral demyelinating phenotype resembling CCALD, to slow disease progression over decades, or adrenal insufficiency only. Approximately 50% of female heterozygotes develop moderate spastic paresis resembling the AMN phenotype. This review focuses on current experiences with different therapeutic approaches. Lorenzo's oil did not prove to be effective in cerebral inflammatory disease variants, but asymptomatic patients, and speculatively AMN variants without cerebral involvement, as well as female carriers may benefit from early intake of oleic and erucic acids in addition to VLCFA restriction. Hormone-replacement therapy is necessary in all patients with adrenal insufficiency. Hematopoietic stem cell transplantation has been reported to be effective in presymptomatic or early symptomatic CCALD, and may well also be a final therapeutic option in early ACALD patients. Early detection of mutation carriers and timely initiation of therapy is important for the effectiveness of all therapeutic efforts. Gene therapy of endogenous hematopoietic stem cells, pharmacological upregulation of other genes encoding proteins involved in peroxisomal beta-oxidation, reduction of oxidative stress, and possibly lovastatin are candidates for future X-ALD therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Putative X-linked adrenoleukodystrophy gene shares unexpected homology with ABC transporters
Mosser, J., Douar, A.-M., Sarde, C.-O., Kioschis, P., Feil, R., Moser, H., Poustka, A.-M., Mandel, J.-L., & Aubourg, P. (1993) · Nature · doi:10.1038/361726a0 · Cited by 1,202 · cited 1×
“In 1981 the X-ALD locus was mapped to chromosome Xq28 [7], and twelve years later, the X-ALD gene (ABCD1) was identified [8,9].”
BackgroundMoser, H. W., Mahmood, A., & Raymond, G. V. (2007) · Nature Clinical Practice Neurology · doi:10.1038/ncpneuro0421 · Cited by 663
Priller, J., Flügel, A., Wehner, T., Boentert, M., Haas, C. A., Prinz, M., Fernández-Klett, F., Prass, K., Bechmann, I., de Boer, B. A., et al. (2001) · Nature Medicine · doi:10.1038/nm1201-1356 · Cited by 637
Qualitative alteration in substrate specificity of mitochondrial monoamine oxidase in brain
Moskvitina, T. A., Kamyshanskaya, N. S., Kaverina, L. P., & Gorkin, V. Z. (1976) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1976.tb04462.x · Cited by 440
Peters, C., Charnas, L. R., Tan, Y., Ziegler, R. S., Shapiro, E. G., DeFor, T., Grewal, S. S., Orchard, P. J., Abel, S. L., Goldman, A. I., et al. (2004) · Blood · doi:10.1182/blood-2003-10-3402 · Cited by 374
Aubourg, P., Blanche, S., Jambaqué, I., Rocchiccioli, F., Kalifa, G., Naud-Saudreau, C., Rolland, M.-O., Debré, M., Chaussain, J.-L., Griscelli, C., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199006283222607 · Cited by 366 · cited 1×
“The first report about a favorable effect of HCT in a CCALD patient was published in 1990 [95] and several subsequent reports in small patients series showed positive results [96-100].”
ResultAxonal loss and neuroinflammation caused by peroxisome-deficient oligodendrocytes
Kassmann, C. M., Lappe-Siefke, C., Baes, M., Brügger, B., Mildner, A., Werner, H. B., Natt, O., Michaelis, T., Prinz, M., Frahm, J., et al. (2007) · Nature Genetics · doi:10.1038/ng2070 · Cited by 357
Shapiro, E., Krivit, W., Lockman, L., Jambaqué, I., Peters, C., Cowan, M., Harris, R., Blanche, S., Bordigoni, P., Loes, D., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02629-5 · Cited by 329 · cited 2×
“A smaller study monitored VLCFA before HCT and during follow-up and demonstrated a mean decrease of 55% within 2 years after HCT reaching mean VLCFA levels as found in heterozygotes [102].”
BackgroundAdrenoleukodystrophy: Incidence, new mutation rate, and results of extended family screening
Bezman, L., Moser, A. B., Raymond, G. V., Rinaldo, P., Watkins, P. A., Smith, K. D., Kass, N. E., & Moser, H. W. (2001) · Annals of Neurology · doi:10.1002/ana.101 · Cited by 324
Kemp, S., Pujol, A., Waterham, H. R., van Geel, B. M., Boehm, C. D., Raymond, G. V., Cutting, G. R., Wanders, R. J. A., & Moser, H. W. (2001) · Human Mutation · doi:10.1002/humu.1227 · Cited by 321
A mouse model for X-linked adrenoleukodystrophy
Lu, J.-F., Lawler, A. M., Watkins, P. A., Powers, J. M., Moser, A. B., Moser, H. W., & Smith, K. D. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.17.9366 · Cited by 293 · cited 2×
“nor adrenal insufficiency like seen in human X-ALD [57-59].”
BackgroundPOWERS, J. M., LIU, Y., MOSER, A. B., & MOSER, H. W. (1992) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199211000-00007 · Cited by 265
A Two-Year Trial of Oleic and Erucic Acids (“Lorenzo's Oil”) as Treatment for Adrenomyeloneuropathy
Aubourg, P., Adamsbaum, C., Lavallard-Rousseau, M.-C., Rocchiccioli, F., Cartier, N., Jambaque, I., Jakobezak, C., Lemaitre, A., Boureau, F., Wolf, C., et al. (1993) · New England Journal of Medicine · doi:10.1056/nejm199309093291101 · Cited by 242 · cited 2×
“(GTO) and glyceryl trierucate (GTE), referred to as Lorenzo’s Oil (LO), can normalize the highly elevated concentrations of VLCFA in the plasma of boys with X-ALD, probably by competitive inhibition with the microsomal elongating system for saturated long chain fatty acids [77-80].”
BackgroundFollow-up of 89 asymptomatic patients with adrenoleukodystrophy treated with Lorenzo's oil
Moser, H. W., Raymond, G. V., Lu, S.-E., Muenz, L. R., Moser, A. B., Xu, J., Jones, R. O., Loes, D. J., Melhem, E. R., Dubey, P., et al. (2005) · Archives of Neurology · doi:10.1001/archneur.62.7.1073 · Cited by 239 · cited 2×
“It has been recommended that brain MRI should be obtained at 6 month intervals between 3 and 10 year old boys and yearly thereafter [13,83,94].”
BackgroundSingh, I., Moser, A. E., Moser, H. W., & Kishimoto, Y. (1984) · Pediatric Research · doi:10.1203/00006450-198403000-00016 · Cited by 234
Pujol, A. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.5.499 · Cited by 214
Early oxidative damage underlying neurodegeneration in X-adrenoleukodystrophy
Fourcade, S., Lopez-Erauskin, J., Galino, J., Duval, C., Naudi, A., Jove, M., Kemp, S., Villarroya, F., Ferrer, I., Pamplona, R., et al. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn085 · Cited by 214 · cited 1×
“Recently, it was shown that elevated VLCFA are highly toxic to brain cells due to mitochondrial dysfunction [42] or impairment of oxidative stress homeostasis [43].”
BackgroundMoser, H. W., Loes, D. J., Melhem, E. R., Raymond, G. V., Bezman, L., Cox, C. S., & Lu, S.-E. (2000) · Neuropediatrics · doi:10.1055/s-2000-9236 · Cited by 210
Dietary erucic acid therapy for X‐linked adrenoleukodystrophy
Rizzo, W. B., Leshner, R. T., Odone, A., Dammann, A. L., Craft, D. A., Jensen, M. E., Jennings, S. S., Davis, S., Jaitly, R., & Sgro, J. A. (1989) · Neurology · doi:10.1212/wnl.39.11.1415 · Cited by 207
Pujol, A., Ferrer, I., Camps, C., Metzger, E., Hindelang, C., Callizot, N., Ruiz, M., Pàmpols, T., Giròs, M., & Mandel, J. L. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh323 · Cited by 201 · cited 12×
“ABCD2 expression can be enhanced by pharmacological agents like fibrates [34,61].”
BackgroundInfluentialHo, J. K., Moser, H., Kishimoto, Y., & Hamilton, J. A. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118182 · Cited by 199 · cited 1×
“It was suggested that inclusion of VLCFA into cell membranes disrupts membrane structure [41].”
BackgroundKobayashi, T., Shinnoh, N., Kondo, A., & Yamada, T. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6340 · Cited by 197
Mahmood, A., Raymond, G. V., Dubey, P., Peters, C., & Moser, H. W. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70177-1 · Cited by 193
Hein, S., Schonfeld, P., Kahlert, S., & Reiser, G. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn066 · Cited by 180 · cited 1×
“Recently, it was shown that elevated VLCFA are highly toxic to brain cells due to mitochondrial dysfunction [42] or impairment of oxidative stress homeostasis [43].”
BackgroundNetik, A., Forss-Petter, S., Holzinger, A., Molzer, B., Unterrainer, G., & Berger, J. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.5.907 · Cited by 148
Role of ALDP (ABCD1) and Mitochondria in X-Linked Adrenoleukodystrophy
McGuinness, M. C., Lu, J.-F., Zhang, H.-P., Dong, G.-X., Heinzer, A. K., Watkins, P. A., Powers, J., & Smith, K. D. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.2.744-753.2003 · Cited by 147
Dubey, P., Raymond, G. V., Moser, A. B., Kharkar, S., Bezman, L., & Moser, H. W. (2005) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2004.10.067 · Cited by 145 · cited 1×
“It has a high prevalence in otherwise asymptomatic boys with X-ALD and is a frequent cause of morbidity which can be prevented by careful monitoring and timely initiation of therapy [72].”
BackgroundAdrenoleukodystrophy: New Approaches to a Neurodegenerative Disease
Moser, H. W., Raymond, G. V., & Dubey, P. (2005) · JAMA · doi:10.1001/jama.294.24.3131 · Cited by 142
Berger, J., Molzer, B., Fae, I., & Bernheimer, H. (1994) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1994.2855 · Cited by 126
Ito, M., Blumberg, B. M., Mock, D. J., Goodman, A. D., Moser, A. B., Moser, H. W., Smith, K. D., & Powers, J. M. (2001) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/60.10.1004 · Cited by 125
Cerebral adrenoleukodystrophy (ALD) in only one of monozygotic twins with an identical ALD genotype
Korenke, G. C., Wilichowski, E., Hunneman, D. H., Hanefeld, F., Fuchs, S., Krasemann, E., & Doerr, H. G. (1996) · Annals of Neurology · doi:10.1002/ana.410400221 · Cited by 117
Spastic paraplegia associated with Addison’s disease: Adult variant of adreno-leukodystrophy
Budka, H., Sluga, E., & Heiss, W.-D. (1976) · Journal of Neurology · doi:10.1007/bf00312873 · Cited by 115
HUBBARD, W., MOSER, A., TORTORELLI, S., LIU, A., JONES, D., & MOSER, H. (2006) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2006.05.001 · Cited by 108
Berger, J., Albet, S., Bentejac, M., Netik, A., Holzinger, A., Roscher, A. A., Bugaut, M., & Forss‐Petter, S. (1999) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.1999.00772.x · Cited by 106 · cited 1×
“However, drugs to be identified suitable for pharmacological up-regulation of ALDRP and/or PMP70 have to be able to cross the blood brain barrier, which is not the case for many candidate drugs such as fenofibrate [113,114].”
BackgroundMutational analysis of patients with X-linked adrenoleukodystrophy
Kok, F., Neumann, S., Sarde, C.-O., Zheng, S., Wu, K.-H., Wei, H.-M., Bergin, J., Watkins, P. A., Gould, S., Sack, G., et al. (1995) · Human Mutation · doi:10.1002/humu.1380060203 · Cited by 103 · cited 1×
“Thus, yet unidentified modifier genes and other co-factors are likely to modulate the phenotypic variation, and disease severity [45-48].”
BackgroundIdentification of female carriers of adrenoleukodystrophy
Moser, H. W., Moser, A. E., Trojak, J. E., & Supplee, S. W. (1983) · The Journal of Pediatrics · doi:10.1016/s0022-3476(83)80775-6 · Cited by 99 · cited 1×
“Plasma VLCFA are increased in most female carriers, but false negative or equivocal results occur in up to 20% of obligate heterozygotes, and normal plasma VLCFA levels thus do not exclude heterozygosity for X-ALD [5,26,27].”
BackgroundElongation of very long-chain fatty acids is enhanced in X-linked adrenoleukodystrophy
Kemp, S., Valianpour, F., Denis, S., Ofman, R., Sanders, R.-J., Mooyer, P., Barth, P. G., & Wanders, R. J. A. (2005) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2004.09.015 · Cited by 97
Genomic organization of the adrenoleukodystrophy gene
Sarde, C.-O., Mosser, J., Kioschis, P., Kretz, C., Vicaire, S., Aubourg, P., Poustka, A., & Mandel, J.-L. (1994) · Genomics · doi:10.1006/geno.1994.1339 · Cited by 82
Kemp, S., & Wanders, R. J. A. (2007) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2006.10.001 · Cited by 82 · cited 5×
“ABCD2 expression can be enhanced by pharmacological agents like fibrates [34,61].”
BackgroundInfluentialKishimoto, Y., Moser, H. W., Kawamura, N., Platt, M., Pallante, S. L., & Fenselau, C. (1980) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(80)91182-1 · Cited by 79 · cited 1×
“Neurologically asymptomatic or presymptomatic patients 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 VLCFA accumulation, which is suspected to be a crucial factor in the pathogenesis of X-ALD, originates from both diet and endogenous synthesis [73,74].”
BackgroundThe neuropsychiatry of adult-onset adrenoleukodystrophy
Rosebush, P. I., Garside, S., Levinson, A. J., & Mazurek, M. F. (1999) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/jnp.11.3.315 · Cited by 72 · cited 1×
“Most commonly, these patients manifest signs of mania including dysinhibition, impulsivity, increased spending, hypersexuality, loudness, and perseveration [110,111].”
BackgroundBenhamida, S., Pflumio, F., Dubart-Kupperschmitt, A., Zhao-Emonet, J.-C., Cavazzana-Calvo, M., Rocchiccioli, F., Fichelson, S., Aubourg, P., Charneau, P., & Cartier, N. (2003) · Molecular Therapy · doi:10.1016/s1525-0016(03)00002-9 · Cited by 61 · cited 1×
“24 25 26 27 of ALD protein in monocytes/macrophages derived from engrafted stem cells [126].”
BackgroundNaidu, S. (1988) · Archives of Neurology · doi:10.1001/archneur.1988.00520320032011 · Cited by 55
Restuccia, D. (1997) · Brain · doi:10.1093/brain/120.7.1139 · Cited by 53 · cited 1×
“However, subtle signs of long spinal tract involvement may be detected in neurophysiological investigations [22].”
BackgroundLate-onset adrenoleukodystrophy associated with long-standing psychiatric symptoms
Garside, S., Rosebush, P. I., Levinson, A. J., & Mazurek, M. F. (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0708 · Cited by 51
Haematopoietic stem cell transplantation in 12 patients with cerebral X-linked adrenoleukodystrophy
Baumann, M., Korenke, C., Weddige-Diedrichs, A., Wilichowski, E., Hunneman, D., Wilken, B., Brockmann, K., Klingebiel, T., Niethammer, D., Kühl, J., et al. (2003) · European Journal of Pediatrics · doi:10.1007/s00431-002-1097-3 · Cited by 47 · cited 1×
“Follow-up studies demonstrated that the beneficial effect is maintained for 5-10 years [101,102].”
BackgroundHigh dose immunoglobulin IV treatment in adrenoleukodystrophy.
Cappa, M., Bertini, E., del Balzo, P., Cambiaso, P., Di Biase, A., & Salvati, S. (1994) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.57.suppl.69 · Cited by 44 · cited 1×
“However immunosuppression or immunomodulating therapies with cytoxan [67,68], β-interferon [69], intravenous immunoglobins [70], and modified cobratoxin [71] were ineffective.”
BackgroundAdrenoleukodystrophy: Failure of Immunosuppression to Prevent Neurological Progression
Stumpf, D. A. (1981) · Archives of Neurology · doi:10.1001/archneur.1981.00510010074014 · Cited by 41 · cited 1×
“However immunosuppression or immunomodulating therapies with cytoxan [67,68], β-interferon [69], intravenous immunoglobins [70], and modified cobratoxin [71] were ineffective.”
BackgroundVery‐late‐onset adrenoleukodystrophy: Possible precipitation of demyelination by cerebral contusion
Weller, M., Liedtke, W., Petersen, D., Opitz, H., & Poremba, M. (1992) · Neurology · doi:10.1212/wnl.42.2.367 · Cited by 33
Self-citationMethionine metabolism and phenotypic variability in X-linked adrenoleukodystrophy
Linnebank, M., Kemp, S., Wanders, R. J. A., Kleijer, W. J., van der Sterre, M. L. T., Gärtner, J., Fliessbach, K., Semmler, A., Sokolowski, P., Köhler, W., et al. (2006) · Neurology · doi:10.1212/01.wnl.0000196491.42058.6f · Cited by 22
Self-citation
Cited by
General aspects and neuropathology of X-linked adrenoleukodystrophy
Ferrer, I., Aubourg, P., & Pujol, A. (2010) · Brain Pathology · doi:10.1111/j.1750-3639.2010.00390.x · Cited by 139
Myelin peroxisomes–Essential organelles for the maintenance of white matter in the nervous system
Kassmann, C. M. (2014) · Biochimie · doi:10.1016/j.biochi.2013.09.020 · Cited by 72
Adrenoleukodystrophy in female heterozygotes: underrecognized and undertreated
Jangouk, P., Zackowski, K. M., Naidu, S., & Raymond, G. V. (2012) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2011.11.001 · Cited by 63
Khan, M., Singh, J., Gilg, A. G., Uto, T., & Singh, I. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m002329 · Cited by 49
Haynes, C. A., & De Jesús, V. R. (2012) · Clinica Chimica Acta · doi:10.1016/j.cca.2012.03.026 · Cited by 46
Metadata
- Authors
- Semmler, A., Köhler, W., Jung, H. H., Weller, M., & Linnebank, M.
- Venue
- Expert Review of Neurotherapeutics
- Publisher
- Informa UK Limited
- Published
- 2008-09
- Volume
- 8
- Issue
- 9
- Pages
- 1367-1379
- ISSN
- 1473-7175 (ISSN-L)
- 1744-8360
- OpenAlex
- W2145948329
- Cited by
- 50
- References
- 50
- FWCI
- 2.19
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.